Szyman Catherine M.
Known title: DirectorCIK: 0001438538
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.
Transaction History
| EW | ▼ Sell | Tax Withholding | 5,530 | $387K | 9/3/2024 | View on chart |
| EW | ▲ Buy | Grant | 10,910 | $0 | 9/3/2024 | View on chart |
| EW | ▼ Sell | Tax Withholding | 258 | $24K | 7/7/2024 | View on chart |
| EW | ▼ Sell | Tax Withholding | 827 | $72K | 5/11/2024 | View on chart |
| EW | ▲ Buy | Grant | 32,025 | $0 | 5/7/2024 | View on chart |
| EW | ▼ Sell | Tax Withholding | 609 | $52K | 5/7/2024 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,796 | $0 | 5/4/2024 | View on chart |
| EW | ▼ Sell | Tax Withholding | 3,442 | $293K | 5/4/2024 | View on chart |
| EW | ▼ Sell | Tax Withholding | 479 | $41K | 5/3/2024 | View on chart |
| EW | ▲ Buy | Grant | 8,560 | $0 | 2/22/2024 | View on chart |
| EW | ▲ Buy | Option Exercise | 27,000 | $992K | 2/15/2024 | View on chart |
| EW | ▼ Sell | Open Market | 27,000 | $2.3M | 2/15/2024 | View on chart |
| EW | ▲ Buy | Option Exercise | 20,000 | $735K | 2/13/2024 | View on chart |
| EW | ▼ Sell | Open Market | 20,000 | $1.7M | 2/13/2024 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,000 | $184K | 10/10/2023 | View on chart |
| EW | ▼ Sell | Open Market | 5,000 | $363K | 10/10/2023 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,000 | $184K | 9/8/2023 | View on chart |
| EW | ▼ Sell | Open Market | 5,000 | $380K | 9/8/2023 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,000 | $184K | 8/9/2023 | View on chart |
| EW | ▼ Sell | Open Market | 5,000 | $393K | 8/9/2023 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,000 | $184K | 7/10/2023 | View on chart |
| EW | ▼ Sell | Open Market | 5,000 | $453K | 7/10/2023 | View on chart |
| EW | ▼ Sell | Tax Withholding | 252 | $23K | 7/7/2023 | View on chart |
| EW | ▲ Buy | Option Exercise | 5,000 | $184K | 6/13/2023 | View on chart |
| EW | ▼ Sell | Open Market | 5,000 | $429K | 6/13/2023 | View on chart |
| OM | ▲ Buy | Grant | 7,681 | $0 | 5/31/2023 | View on chart |
| EW | ▲ Buy | Grant | 6,525 | $0 | 5/11/2023 | View on chart |
| EW | ▲ Buy | Option Exercise | 75,600 | $2.7M | 5/9/2023 | View on chart |
| EW | ▼ Sell | Open Market | 75,600 | $6.7M | 5/9/2023 | View on chart |
| EW | ▼ Sell | Tax Withholding | 1,376 | $122K | 5/8/2023 | View on chart |
| EW | ▲ Buy | Option Exercise | 4,708 | $0 | 5/7/2023 | View on chart |
| EW | ▼ Sell | Tax Withholding | 2,154 | $191K | 5/7/2023 | View on chart |
| EW | ▼ Sell | Tax Withholding | 344 | $30K | 5/4/2023 | View on chart |
| EW | ▼ Sell | Tax Withholding | 327 | $29K | 5/3/2023 | View on chart |
| EW | ▲ Buy | Grant | 2,032 | $0 | 7/7/2022 | View on chart |
| OM | ▲ Buy | Grant | 6,880 | $0 | 5/31/2022 | View on chart |
| EW | ▼ Sell | Tax Withholding | 1,730 | $166K | 5/17/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 12,206 | $0 | 5/8/2022 | View on chart |
| EW | ▼ Sell | Tax Withholding | 7,428 | $747K | 5/8/2022 | View on chart |
| EW | ▼ Sell | Tax Withholding | 595 | $60K | 5/7/2022 | View on chart |
| EW | ▼ Sell | Tax Withholding | 493 | $52K | 5/4/2022 | View on chart |
| EW | ▼ Sell | Open Market | 3,796 | $402K | 5/4/2022 | View on chart |
| EW | ▼ Sell | Open Market | 9,155 | $954K | 5/4/2022 | View on chart |
| EW | ▼ Sell | Open Market | 10,449 | $1.1M | 5/4/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 23,400 | $509K | 5/4/2022 | View on chart |
| EW | ▲ Buy | Grant | 3,775 | $0 | 5/3/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 20,000 | $435K | 4/11/2022 | View on chart |
| EW | ▼ Sell | Open Market | 3,600 | $440K | 4/11/2022 | View on chart |
| EW | ▼ Sell | Open Market | 6,579 | $809K | 4/11/2022 | View on chart |
| EW | ▼ Sell | Open Market | 9,821 | $1.2M | 4/11/2022 | View on chart |
| EW | ▼ Sell | Open Market | 8,147 | $850K | 3/14/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 20,000 | $435K | 3/14/2022 | View on chart |
| EW | ▼ Sell | Open Market | 11,853 | $1.2M | 3/14/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 20,000 | $435K | 2/18/2022 | View on chart |
| EW | ▼ Sell | Open Market | 6,900 | $730K | 2/18/2022 | View on chart |
| EW | ▼ Sell | Open Market | 13,100 | $1.4M | 2/18/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 10,000 | $218K | 1/14/2022 | View on chart |
| EW | ▼ Sell | Open Market | 1,116 | $134K | 1/14/2022 | View on chart |
| EW | ▼ Sell | Open Market | 8,884 | $1.1M | 1/14/2022 | View on chart |
| EW | ▼ Sell | Open Market | 10,000 | $1.2M | 12/17/2021 | View on chart |
| EW | ▲ Buy | Option Exercise | 10,000 | $218K | 12/17/2021 | View on chart |
| EW | ▲ Buy | Option Exercise | 10,000 | $218K | 11/18/2021 | View on chart |
| EW | ▼ Sell | Open Market | 1,253 | $149K | 11/18/2021 | View on chart |
| EW | ▼ Sell | Open Market | 2,390 | $280K | 11/18/2021 | View on chart |
| EW | ▼ Sell | Open Market | 6,357 | $749K | 11/18/2021 | View on chart |
| EW | ▼ Sell | Open Market | 7,138 | $787K | 10/18/2021 | View on chart |
| EW | ▲ Buy | Option Exercise | 9,741 | $212K | 10/18/2021 | View on chart |
| EW | ▼ Sell | Open Market | 2,603 | $289K | 10/18/2021 | View on chart |
| EW | ▲ Buy | Option Exercise | 9,741 | $212K | 9/8/2021 | View on chart |
| EW | ▼ Sell | Open Market | 9,741 | $1.2M | 9/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death
The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.